Acute Phase Postherpetic Neuralgia
Conditions
Interventions
Experimental Group:Conventional Western medicine therapy combined with surrounding needling and topical application of Polygonum perfoliatum L. gel plaster
Control Group 1:Conventional Western medicine therapy combined with surrounding needling and a placebo plaster
Control Group 2:Conventional Western medicine therapy
Sponsors
The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Meeting the diagnostic criteria for acute phase postherpetic neuralgia according to both Traditional Chinese Medicine and Western medicine; 2) Aged between 18 and 75 years (with an Activity of Daily Living Scale (ADL) score = 60), regardless of gender; 3) A score of = 6 on the worst pain item of the Zoster Brief Pain Inventory (ZBPI) within the past 24 hours; 4) Herpes zoster lesions localized to unilateral thoracic, abdominal, lumbodorsal, or limb regions; 5) In the papule or vesicle stage, with rash onset within 1-3 days, and having received no prior treatment; 6) Patients who are informed of and consent to the trial content and protocol, and have signed the informed consent form. Note: Patients must meet all of the above six criteria to be included in this study.
Exclusion criteria
Exclusion criteria: 1) Failure to meet the diagnostic criteria and inclusion criteria of this study; pregnant or lactating women; individuals allergic to any component of the Polygonum perfoliatum L. gel preparation; 2) Patients with mental disorders such as depression or anxiety requiring medication; individuals with intellectual disabilities who are unable to cooperate with questionnaires; 3) Patients with concurrent progressive malignant tumors and/or other severe diseases of the cardiovascular, cerebrovascular, hepatic, or renal systems; those with existing moderate-to-severe hepatic or renal insufficiency, severe infections, or coagulation disorders; 4) Patients currently participating in other clinical trials. Note: Subjects meeting any one of the above criteria shall not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Zoster Brief Pain Inventory; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to cessation of new vesicle formation;Time to crusting;Time to decrustation;Pain area;Time to pain relief;Zoster Brief Pain Inventory (ZBPI) pain severity score;Incidence of postherpetic neuralgia;7-tiem generalized anxiety disorder scale;patients healthquestion aire depression scale-9 item;Pittsburgh sleep quality index;Neuron-specific enolase (NSE);Interleukin-6 (IL-6); | — |
Countries
China
Contacts
Public ContactCuijin
Guizhou University of Traditional Chinese Medicine
Outcome results
None listed